Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) (2016 - 2021)
Historic EPS (Weighted Average and Diluted) for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $0.23.
- Neurocrine Biosciences' EPS (Weighted Average and Diluted) rose 13709.68% to $0.23 in Q3 2021 from the same period last year, while for Sep 2021 it was $4.57, marking a year-over-year increase of 39139.78%. This contributed to the annual value of $4.16 for FY2020, which is 99248.89% up from last year.
- Neurocrine Biosciences' EPS (Weighted Average and Diluted) amounted to $0.23 in Q3 2021, which was up 13709.68% from $0.43 recorded in Q2 2021.
- Over the past 5 years, Neurocrine Biosciences' EPS (Weighted Average and Diluted) peaked at $3.58 during Q4 2020, and registered a low of -$1.12 during Q1 2019.
- In the last 5 years, Neurocrine Biosciences' EPS (Weighted Average and Diluted) had a median value of $0.23 in 2021 and averaged $0.21.
- Examining YoY changes over the last 5 years, Neurocrine Biosciences' EPS (Weighted Average and Diluted) showed a top increase of 92309.77% in 2020 and a maximum decrease of 21071.43% in 2020.
- Neurocrine Biosciences' EPS (Weighted Average and Diluted) (Quarter) stood at $0.07 in 2017, then surged by 164.98% to $0.2 in 2018, then surged by 77.49% to $0.35 in 2019, then soared by 923.1% to $3.58 in 2020, then plummeted by 93.58% to $0.23 in 2021.
- Its EPS (Weighted Average and Diluted) was $0.23 in Q3 2021, compared to $0.43 in Q2 2021 and $0.33 in Q1 2021.